Health Canada approves first generic version of Novo Nordisk's Ozempic [BNN Bloomberg (Canada)]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: BNN Bloomberg
Several drugmakers have been developing lower-cost versions of Novo Nordisk's diabetes drug Ozempic, driving down monthly prices for some users. In March, India became the first major market to introduce copycat versions of semaglutide following the expiry of certain patent protections, prompting Novo Nordisk to cut prices for Ozempic and its obesity drug Wegovy in the country. Health Canada said it is reviewing eight other applications for generic semaglutide from different companies and expects to make more decisions in the coming weeks and months. In Canada, many generic medications are 45 to 90 per cent cheaper than the brand-name versions. Dr. Reddy's and Novo Nordisk did not immediately respond to Reuters' requests for comment. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Tasim Zahid)
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug [Yahoo! Finance]Yahoo! Finance
- Eli Lilly investors are eager for Foundayo insight after early launch data [Yahoo! Finance]Yahoo! Finance
- Eli Lilly investors are eager for Foundayo insight after early launch data [Yahoo! Finance Canada]Yahoo! Finance Canada
- Wegovy's Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website